Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. - Wikidata - awgldk - TriplyDB

Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.

Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.

http://www.wikidata.org/entity/Q35888710

about

NK Cells in HIV Disease A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Systems serology for evaluation of HIV vaccine trials.Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Fc functional antibodies in humans with severe H7N9 and seasonal influenza HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.HIV antibodies for treatment of HIV infection.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.The association of HIV-1 Gag-specific IgG antibodies with natural control of HIV-1 infection in individuals not carrying HLA-B*57: 01 is only observed in viremic controllers.Memory B Cells, the HLA-B*57 Allele and Natural Control of HIV Infection.IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.Phenotypic and Functional Characterization of Circulatory, Splenic, and Hepatic NK Cells in Simian Immunodeficiency Virus-Controlling Macaques.Natural Killer cells in HIV-1 infection and therapy.Temporal variation in HIV-specific IgG subclass Abs during acute infection differentiates spontaneous controllers from chronic progressors.Systems serology: profiling vaccine induced humoral immunity against HIV.Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization.Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination.Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates.The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir.Beyond binding: antibody effector functions in infectious diseases.Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens.A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples.Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.

P2860

Q26752833-34F738B0-351F-4299-994D-3F6888049A2E Q30234577-1D5A85D7-3A1C-4A80-8D79-E86F09F4E878 Q30238729-849C472B-6ED5-4B1B-8B37-EDCFA5B49970 Q30390233-FB0D9CA1-4757-4A3E-93D2-B0E1BF7143D1 Q33865785-9BFF7BB8-6DF1-45CA-AF24-9C12C87B3471 Q33867299-06D6E1C1-689D-4D23-AF65-8060F755FF5D Q33877811-E5117BD5-A3AE-4C23-AAFA-DCDDC682E6F2 Q34537743-8939E50F-2796-444A-B18D-41879488E47B Q36118373-97426ADC-333F-4AA5-862A-66E63CECDBE2 Q37363561-C08F4752-2875-4FCD-BA50-C0286DABF0B4 Q37592654-DB44A5BB-13DC-42B1-99D2-471396274513 Q37646897-65BDBB1F-0ABE-447B-9D0D-B8C24C248EE3 Q37677278-AC09D33E-B18E-4AC3-BC9E-A441F83252F0 Q38682077-14B380E7-C82D-44E7-96C8-09BF24E4612F Q38717198-BC52FEFB-43E7-477F-9F0B-ECA609E0225F Q38718440-189C2675-0CA8-4086-BC11-B9CA2B169E86 Q38719420-0FCB2ED9-45EE-48FB-B3A4-494F43FE7DB0 Q38727815-3A56BF90-C085-455D-92CB-552A64D04D64 Q39108716-6C71EC85-D462-49A7-A6D5-86B9FCEBB2E1 Q39189458-FDE6A994-56CA-413E-A753-24380E7886FF Q40159913-3287C6A3-FBA2-4D9D-9B11-4FB0E4AB1F60 Q40163730-772FA28B-5272-4C1B-A87D-B52FB04BDB9A Q40166485-F4DCF76A-499D-43A1-BF2C-2B49AA60FBF3 Q40322235-07993360-22D0-4E70-8900-C74F0A4232F5 Q40695938-F981A975-1553-45E9-81D5-7243C349C797 Q41924059-ED300F08-2C8B-43C9-8875-DC92D29FD910 Q41930380-549F9ABD-D3FB-45C0-928E-79A0A60C2D8E Q41934634-6F537F71-0C4D-477E-9F81-BC58EB298846 Q46632788-39A3DA33-3EEC-472B-83A6-6CBB0163C4B6 Q47104983-F8EB1BDB-A2C2-4720-954C-CB337512169D Q47364595-53FA3573-C0B2-43F4-B311-6A7693258908 Q47384731-B30619F1-80D7-4831-B1DD-B7E880379FC3 Q47582681-98CAC6E8-EF69-4B6E-99E2-406351D40643 Q47600020-BA26C888-9814-4772-925E-6455348FEDBF Q47602559-AB591F81-3C80-4C79-9CD1-B6919CB142F6 Q49353060-A4843DB1-7B1B-4DBC-A077-D7124F9BEA4A Q49647394-C324FFC4-5940-4110-954B-32C4A1B78D3D Q50209602-FA7F41AE-DE70-43FF-9F72-4D4610747D4E Q52561260-4788FB14-5B46-463C-8AB9-C26637DBACCA Q52598776-E9DA0471-72E6-4A71-AC4F-7237819A098F

P2860

Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control.

http://www.wikidata.org/entity/Q35888710

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@ast

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@en

type

label

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@ast

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@en

prefLabel

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@ast

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@en

P1433

Q35888710-4F5D6E30-97C3-4135-A383-D4422397893D

P1476

Q35888710-C8DE84EC-9DA1-455C-9456-A50BB8041387

P2093

Q35888710-0557396F-F752-4DCE-826D-69D9047486F5

Q35888710-209BFB67-F435-453D-8D75-2D4A9E2336DC

Q35888710-25342263-B2B0-4DB5-8C3B-913B78CBA507

Q35888710-86667193-7774-486C-BE49-62555168EE76

Q35888710-87A66384-CE4F-4A30-BF55-51FAE248B207

Q35888710-8DF416DF-5001-4069-BA2B-DFB336CD4F1D

Q35888710-ED937B8D-38F8-4B18-A9E7-95AD26808D15

P2860

Q35888710-0047780C-0A34-400A-BDFC-129790CAF7CE

Q35888710-007E65DF-D9C1-4C59-9D7D-FA632DCF3528

Q35888710-011111C8-9A46-4688-8E83-AF71CACBDBA4

Q35888710-01811636-BC3B-4B91-A51F-315C4C73E62C

Q35888710-061E86E4-6A8F-44C5-BCE9-87CD13330C9B

Q35888710-0D7526FF-32ED-4BE4-89D3-33E4B86EE475

Q35888710-120238ED-A7C8-4D69-8127-129D65096862

Q35888710-139C9203-7199-44D8-8D35-7D81BF55CF9E

Q35888710-15F0A5D0-A080-4CF3-82F2-9637D12CEADD

Q35888710-284626B1-3D2F-4116-B463-2F2E324B60EF

P304

Q35888710-F5336A37-D5D3-42EC-88F9-BE2CBDEA3850

P31

Q35888710-6341C1F8-1EF1-4B5C-AEA4-4C7046EB41EA

P356

Q35888710-9A619808-3DA2-4FB2-B73A-94D11B8E5172

P433

Q35888710-BED6F8FA-1238-490C-9142-4C07262300D9

P478

Q35888710-5F164953-10D8-4B2A-A523-BC0C4DE58CCC

P50

Q35888710-50E6BB0D-B56B-4F8C-A47D-0174BDB63277

P577

Q35888710-6549C2FA-F53C-46CA-A6EC-8065CE67A5D1

P5875

Q35888710-37FD1A20-FDEF-4697-9B93-974821FCF11E

P698

Q35888710-F5E25AD1-D1B6-43C4-8C8A-8AB87591C018

P921

Q35888710-5B8B4673-37FA-442A-9EBA-5AC8F61E82DE

P932

Q35888710-DCB08013-41E7-4989-9F90-9FEC89C67647

P356

JOURNAL.PPAT.1005315

P1433

P1476

Polyfunctional HIV-Specific An ...... with Spontaneous HIV Control.

@en

P2093

Anastassia Mikhailova

http://www.w3.org/2001/XMLSchema#string

Chris Bailey-Kellogg

http://www.w3.org/2001/XMLSchema#string

Eric P Brown

http://www.w3.org/2001/XMLSchema#string

Galit Alter

http://www.w3.org/2001/XMLSchema#string

Karen G Dowell

http://www.w3.org/2001/XMLSchema#string

Margaret E Ackerman

http://www.w3.org/2001/XMLSchema#string

Todd J Suscovich

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads

High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples

Regularization Paths for Generalized Linear Models via Coordinate Descent

A whole-genome association study of major determinants for host control of HIV-1

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

P304

e1005315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1005315

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Bruce D. Walker

P577

2016-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289686843

http://www.w3.org/2001/XMLSchema#string

P698

26745376

http://www.w3.org/2001/XMLSchema#string

P921

P932

4706315

http://www.w3.org/2001/XMLSchema#string